X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Atorvastatin is the most prescribed statin for lowering cholesterol worldwide — and at the same time the one with the most therapy discontinuations. Around one in three adults in Germany has elevated cholesterol levels (a German figure, broadly similar across Western countries), and considerably more in older age groups. Anyone who stops on their own because of muscle pain loses one of the most important protective factors against heart attack and stroke — yet in most cases the problem can be solved with a dose adjustment or a different statin.
See more detail.gif)
Never stop atorvastatin on your own — the cardiovascular protection as a rule outweighs the side effects. With dark urine and muscle pain (suspicion of rhabdomyolysis), call the emergency services immediately (112; or 999/112 in the UK). Last updated: May 2026.
Atorvastatin is among the most frequently prescribed medications worldwide and is one of the best-researched substances of modern medicine. Below are the most important key facts for a quick orientation — the individual points are explained in detail in the following chapters.
| Property | Details |
|---|---|
| Active substance | Atorvastatin |
| Trade names | Sortis (Germany), Lipitor (international), numerous atorvastatin generics |
| ATC code | C10AA05 |
| Substance class | HMG-CoA reductase inhibitor (statin) |
| Mechanism of action | Inhibition of the body's own cholesterol synthesis in the liver → increased LDL uptake from the blood |
| Bioavailability | about 14% (strong first-pass effect) |
| Half-life | 14 hours (active metabolite 20–30 hours) |
| Dosage form | Film-coated tablets (10, 20, 40, 80 mg) |
| Usual dosage | 10–80 mg/day orally, once daily independent of the time of day |
| LDL lowering | 30–55% depending on the dose |
| Main metabolism | CYP3A4 (a relevant source of interactions) |
| Prescription status | Yes |
| Most important note | Never stop on your own — protection against heart attack and stroke is lost within weeks |
Atorvastatin is a statin — that is, an HMG-CoA reductase inhibitor — and is among the most frequently prescribed medications worldwide of all. In Germany, after simvastatin, it is in second place of the most-prescribed lipid lowerers and is increasingly often prescribed. Atorvastatin lowers LDL cholesterol very effectively — typically by 30 to 55 per cent, depending on the dose — and thereby demonstrably reduces the risk of heart attack, stroke, and cardiovascular death.
Atorvastatin was developed in the 1980s by Pfizer and first approved in 1996. Under the brand name Lipitor (in Germany: Sortis) it was for years the highest-grossing medication in the world. Since the patent expiry in 2011 it is available very cheaply as a generic. In contrast to simvastatin, atorvastatin works reliably even without an evening intake — the longer half-life makes it more flexible in everyday life.
Statins are one of the best-researched medication classes of all — with data from more than 20 large randomised studies in over 170,000 patients. The cardiovascular risk reduction is clearly proven: per 1 mmol/L of LDL lowering, the risk of heart attack and stroke falls by about 22 per cent. Nonetheless, statins are discussed controversially — above all because of muscle side effects, which are frequently the reason for therapy breaks-offs. The scientific reappraisal of recent years has brought important new insights here.
Atorvastatin selectively inhibits the enzyme HMG-CoA reductase in the liver. This enzyme catalyses a key step of the body's own cholesterol synthesis — the conversion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) into mevalonate. Through the inhibition of this enzyme, endogenous cholesterol production is considerably reduced.
The clever consequence of this intervention: the liver cells continue to need cholesterol for their normal functions — and compensate for the "lack" by forming more LDL receptors on their surface and thereby actively taking up LDL cholesterol from the blood. Exactly this mechanism is the actual cardiovascular mechanism of action: the LDL cholesterol in the blood falls, less cholesterol deposits in the vessel walls, atherosclerotic plaques stabilise.
Beyond the pure LDL lowering, statins have a number of pleiotropic effects that contribute to cardiovascular protection: an anti-inflammatory effect, improvement of endothelial function, plaque stabilisation, a slight lowering of triglycerides, a slight rise of HDL cholesterol. These effects explain why statins can bring cardiovascular advantages even in patients with normal LDL values — e.g. after a heart attack has been gone through.
Atorvastatin is well absorbed orally, but has a low bioavailability of about 14 per cent through a strong first-pass effect in the liver. The plasma half-life is 14 hours, the active metabolite has a half-life of 20 to 30 hours — hence the once-daily intake without a strict time-of-day binding. Atorvastatin is metabolised predominantly via CYP3A4 in the liver. This metabolisation is highly relevant clinically — many important interactions arise exactly here.
Atorvastatin has five important indications — all revolve around the lowering of cardiovascular risk:
| Indication | Particular features / target value |
|---|---|
| Hypercholesterolaemia (primary LDL lowering) | LDL target values risk-dependent: low risk < 116 mg/dL, very high risk < 55 mg/dL |
| Secondary prevention after heart attack/stroke/stent | High dose (40–80 mg) independent of the baseline LDL — mortality reduction proven |
| Primary prevention with raised cardiovascular risk | By risk calculation (SCORE2 algorithm); with diabetes, chronic kidney disease, family history |
| Familial hypercholesterolaemia | High-dose, often a combination with ezetimibe or PCSK9 inhibitors — start of therapy possibly already in childhood |
| Atherosclerosis progression / plaque stabilisation | Stabilisation of existing plaques, slight regression possible (proven with imaging) |
The main indication is hypercholesterolaemia; the clearest evidence is present for secondary prevention after a cardiovascular event. More under coronary heart disease.
The right dose of atorvastatin is governed by the indication, the cardiovascular risk, and the individual LDL target value. A doubling of the dose lowers the LDL by about 6 percentage points additionally — the effect does not run linearly, but flattens with higher doses:
| Intensity | Dose | LDL lowering |
|---|---|---|
| Low intensity | 10–20 mg/day | 30–40% |
| Medium intensity | 20–40 mg/day | 40–50% |
| High intensity | 40–80 mg/day | 50–55% |
| Secondary prevention | 40–80 mg/day (as a rule high intensity) | consistent after the event |
| Familial hypercholesterolaemia | often 80 mg/day + ezetimibe or a PCSK9 inhibitor | also > 55% |
| Kidney impairment (eGFR < 30) | no dose reduction required, but higher myopathy caution | — |
| Active liver disease | contraindicated (transaminases > 3× the norm) | — |
Atorvastatin works faster than many other medications: a first LDL lowering is measurable after 1 week, the maximum effect is reached after 4 to 6 weeks. That is why a first lab check of the LDL value usually takes place 4 to 8 weeks after the start of therapy or after a dose change.
Important to understand: unlike with a painkiller, the patient does not directly feel the effect of the statin — the LDL value falls in the blood, the risk of heart attack and stroke falls, but there is no subjective "feeling of effect". This discrepancy between an invisible effect and visible side effects (muscle pain!) is one of the main causes of poor therapy adherence with statins. Education about the "silent protection" is therefore central.
Cardiovascular risk reduction builds up over months to years: the first measurable effects show themselves already after weeks, the full protective effect develops over years — above all through plaque stabilisation and slowing of atherosclerosis. Statin therapy is therefore mostly a lifetime therapy, not a short-term intervention.
Atorvastatin is well tolerated overall — most patients have no noticeable side effects at all. In randomised studies the side-effect rates on statin and placebo are astonishingly similar. Clinically, however, patients frequently report:
| Frequency | Side effect |
|---|---|
| Common (clinically reported) | Muscle pain, muscle weakness, calf cramps — see the separate chapter |
| Common | Gastrointestinal complaints: nausea, constipation, diarrhoea, bloating, abdominal pain |
| Common | Headaches, dizziness — above all in the first weeks |
| Common | Raised liver values — mostly mild and reversible |
| Occasional | Fatigue (often hard to distinguish from the underlying disease) |
| Occasional | Allergic skin reactions — itching, skin rash |
| Occasional | Sleep disturbances, nightmares, vivid dreams |
| Occasional | Taste changes |
| Rare | Peripheral neuropathy (tingling, numbness) — mostly reversible |
| Rare | Tinnitus, sexual dysfunction, weight fluctuations |
| Very rare | Rhabdomyolysis (severe muscle breakdown) — see the myopathy chapter |
Muscle complaints are the most common and most intensively discussed side effect of atorvastatin and all other statins. Here the understanding has deepened considerably in recent years — four degrees of severity are distinguished:
| Form | Clinical picture | Frequency |
|---|---|---|
| SAMS — statin-associated muscle symptoms (without CK rise) | Diffuse muscle pain, muscle weakness, calf cramps, muscle stiffness — typically symmetrical in large muscle groups | in RCT ~1% over placebo; clinically 5–25% |
| Statin myopathy (with CK rise) | Muscle pain with raised creatine kinase (CK) — with CK > 10× the norm myopathy, below that myalgia | rarer than SAMS |
| Rhabdomyolysis | Massive muscle breakdown, CK > 10,000 U/L, myoglobinuria (dark urine), acute kidney failure — life-threatening! | ~1:100,000 per year |
| IMNM — immune-mediated necrotising myopathy | An autoimmune complication with anti-HMGCR antibodies — weakness persists even after stopping; requires immunosuppression | very rare |
The discrepancy between the study frequency (~1%) and clinical practice (5–25%) is explained by the nocebo effect and the difficulty of attributing muscle complaints clearly to the statin — other causes (age, exertion, deficiency states) are common. Risk factors for true statin myopathy: a high statin dose, hypothyroidism, kidney impairment, severe physical exertion, simultaneous CYP3A4 inhibitors, alcohol excess.
Several large meta-analyses have shown that statins raise the risk of the new onset of a type 2 diabetes slightly — by about 9 to 12 per cent over several years. With high statin doses the effect is somewhat more pronounced.
Important for context: the absolute risk increase is small — about 1 additional diabetes case per 1,000 treated patients per year. At the same time, statins prevent 5 to 10 cardiovascular events per year in the same 1,000 patients. The net gain is clearly positive — above all in secondary prevention. Patients with already present diabetes risk factors (obesity, prediabetes, family burden) benefit from a consistent risk management: weight reduction, exercise, a Mediterranean diet.
In patients with existing diabetes, atorvastatin worsens the HbA1c value only slightly — here too the cardiovascular benefit clearly outweighs. More under diabetes.
Atorvastatin can raise liver enzymes — transaminases (ALT, AST) and in rare cases the alkaline phosphatase. Slight rises (up to 3-fold over the norm) are common (5–10 per cent of users), mostly reversible and clinically irrelevant. Serious liver damage is very rare (under 0.5 per cent) and reversible after stopping.
Practical approach: determine liver values before the start of therapy. With active liver disease or transaminases over 3-fold over the norm, atorvastatin is contraindicated. After the start of therapy, a routine check after 8 to 12 weeks, then yearly (more frequently with complaints or risk factors). With a moderate rise, a dose reduction or statin switch — with a massive rise, stopping and re-evaluation.
Important: a fatty liver disease (NAFLD) is not a contraindication for statins — on the contrary, it can even improve under statin therapy. Statin-related liver toxicity is rare and well to manage.
